Can Plus Therapeutics Inc. turn REYOBIQ into a differentiated platform for difficult-to-treat CNS cancers?
Can REYOBIQ change CNS cancer treatment? Discover why Plus Therapeutics Inc.’s latest leptomeningeal metastases data is drawing attention.
Pharma & Biotech
Pharma & Biotech
What Plus Therapeutics Inc.’s SpectronRx partnership reveals about radiopharmaceutical manufacturing readiness
Discover how Plus Therapeutics Inc. is scaling REYOBIQ manufacturing for pivotal trials and what it means for radiopharmaceutical innovation.
Pharma & Biotech
What Eric J. Daniels’ appointment means for Plus Therapeutics and its CNS oncology pipeline
Plus Therapeutics has named Eric J. Daniels as Chief Development Officer. Read what this means for REYOBIQ, CNS oncology execution, and pipeline risk.
Pharma & Biotech
Can REYOBIQ improve Plus Therapeutics’ path in pediatric high-grade glioma and ependymoma?
Plus Therapeutics won orphan drug designation for REYOBIQ in pediatric malignant gliomas. Read what it changes for CNS cancer development.
How REYOBIQ’s latest regulatory milestone may reshape the pediatric neuro-oncology landscape
Plus Therapeutics secures orphan designation for REYOBIQ in pediatric malignant gliomas. Read what this means for trials, exclusivity, and market strategy.